Drug Clinical Trials List

Display 251 - 260 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial	King Abdullah Medical City, Makkah	Ongoing	VITAMIN D3 (CHOLECALCIFEROL)	3	IRB#16-252, V2	KAMC
Bi-weekly Cetuximab and XELIRI(Capecitabine and Irinotecan) as first line therapy in K/N-RAS wild type advanced colorectal cancer: Phase I-II CETUXIRI study	King Faisal Specialist Hospital and Research Centre	Completed	Cetuximab	1/2	1 , 29/07/2015	KFSH&RC-R
Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II	PI initiated	Rejected	Osteoblasts Stem cells	2	2018-01-315	King Fahad University Hospital (Al-Khobar)
Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial.	PI initiated	Rejected	Chondrocytes Stemcells	2	2018-01-314	King Fahad University Hospital (Al-Khobar)
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT)	King Fahad Medical City	Completed	Aspirin	3	ICR-02/ASCOLT	KFMC
An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"	Novartis	Completed	TKI258 / Sorafenib	3	CTKI258A2302	KFSH & RC-R
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE).	Novartis	Rejected	RAD001 (Everolimus)	2	CRAD001LIC01	KFSH & RC-R
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).	Novartis	Completed	INC424 (ruxolitinib)	3b	CINC424A2401	NGHA-R
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Roche	Terminated	Ocrelizumab	3b	MN39159	KFSH&RC-R
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Biogen	Ongoing	Interferon beta-1a	3	105MS306	KFSH&RC-J